Literature DB >> 20543203

Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.

B Pérez1, F Mechinaud, C Galambrun, N Ben Romdhane, B Isidor, N Philip, J Derain-Court, B Cassinat, J Lachenaud, S Kaltenbach, A Salmon, C Désirée, S Pereira, M L Menot, N Royer, O Fenneteau, A Baruchel, C Chomienne, A Verloes, H Cavé.   

Abstract

BACKGROUND: CBL missense mutations have recently been associated with juvenile myelomonocytic leukaemia (JMML), an aggressive myeloproliferative and myelodysplastic neoplasm of early childhood characterised by excessive macrophage/monocyte proliferation. CBL, an E3 ubiquitin ligase and a multi-adaptor protein, controls proliferative signalling networks by downregulating the growth factor receptor signalling cascades in various cell types. METHODS AND
RESULTS: CBL mutations were screened in 65 patients with JMML. A homozygous mutation of CBL was found in leukaemic cells of 4/65 (6%) patients. In all cases, copy neutral loss of heterozygosity of the 11q23 chromosomal region, encompassing the CBL locus, was demonstrated. Three of these four patients displayed additional features suggestive of an underlying developmental condition. A heterozygous germline CBL p.Y371H substitution was found in each of them and was inherited from the father in one patient. The germline mutation represents the first hit, with somatic loss of heterozygosity being the second hit positively selected in JMML cells. The three patients display a variable combination of dysmorphic features, hyperpigmented skin lesions and microcephaly that enable a 'CBL syndrome' to be tentatively delineated. Learning difficulties and postnatal growth retardation may be part of the phenotype.
CONCLUSION: A report of germline mutations of CBL in three patients with JMML is presented here, confirming the existence of an unreported inheritable condition associated with a predisposition to JMML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543203     DOI: 10.1136/jmg.2010.076836

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  49 in total

1.  Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

Authors:  Masako Yaoita; Tetsuya Niihori; Seiji Mizuno; Nobuhiko Okamoto; Shion Hayashi; Atsushi Watanabe; Masato Yokozawa; Hiroshi Suzumura; Akihiko Nakahara; Yusuke Nakano; Tatsunori Hokosaki; Ayumi Ohmori; Hirofumi Sawada; Ohsuke Migita; Aya Mima; Pablo Lapunzina; Fernando Santos-Simarro; Sixto García-Miñaúr; Tsutomu Ogata; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2015-12-29       Impact factor: 4.132

2.  Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.

Authors:  Scott Nadeau; Wei An; Nick Palermo; Dan Feng; Gulzar Ahmad; Lin Dong; Gloria E O Borgstahl; Amarnath Natarajan; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Biochem Anal Biochem       Date:  2012-07-30

3.  Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.

Authors:  Yuka Saito; Yoko Aoki; Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski; Masue Imaizumi; Takeshi Rikiishi; Yoji Sasahara; Shigeo Kure; Tetsuya Niihori; Shigeru Tsuchiya; Seiji Kojima; Yoichi Matsubara
Journal:  Leuk Res       Date:  2012-05-14       Impact factor: 3.156

4.  Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.

Authors:  Yoko Aoki; Tetsuya Niihori; Toshihiro Banjo; Nobuhiko Okamoto; Seiji Mizuno; Kenji Kurosawa; Tsutomu Ogata; Fumio Takada; Michihiro Yano; Toru Ando; Tadataka Hoshika; Christopher Barnett; Hirofumi Ohashi; Hiroshi Kawame; Tomonobu Hasegawa; Takahiro Okutani; Tatsuo Nagashima; Satoshi Hasegawa; Ryo Funayama; Takeshi Nagashima; Keiko Nakayama; Shin-Ichi Inoue; Yusuke Watanabe; Toshihiko Ogura; Yoichi Matsubara
Journal:  Am J Hum Genet       Date:  2013-06-20       Impact factor: 11.025

5.  Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.

Authors:  Michiko Muraoka; Chiho Okuma; Kiichiro Kanamitsu; Hisashi Ishida; Yui Kanazawa; Kana Washio; Masafumi Seki; Motohiro Kato; Junko Takita; Yusuke Sato; Seishi Ogawa; Hirokazu Tsukahara; Megumi Oda; Akira Shimada
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

6.  Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.

Authors:  Anand Pathak; Alexander Pemov; Mary L McMaster; Ramita Dewan; Sarangan Ravichandran; Evgenia Pak; Amalia Dutra; Hyo Jung Lee; Aurelie Vogt; Xijun Zhang; Meredith Yeager; Stacie Anderson; Martha Kirby; Neil Caporaso; Mark H Greene; Lynn R Goldin; Douglas R Stewart
Journal:  Hum Genet       Date:  2015-05-05       Impact factor: 4.132

7.  Exome Sequencing and the Management of Neurometabolic Disorders.

Authors:  Maja Tarailo-Graovac; Casper Shyr; Colin J Ross; Gabriella A Horvath; Ramona Salvarinova; Xin C Ye; Lin-Hua Zhang; Amit P Bhavsar; Jessica J Y Lee; Britt I Drögemöller; Mena Abdelsayed; Majid Alfadhel; Linlea Armstrong; Matthias R Baumgartner; Patricie Burda; Mary B Connolly; Jessie Cameron; Michelle Demos; Tammie Dewan; Janis Dionne; A Mark Evans; Jan M Friedman; Ian Garber; Suzanne Lewis; Jiqiang Ling; Rupasri Mandal; Andre Mattman; Margaret McKinnon; Aspasia Michoulas; Daniel Metzger; Oluseye A Ogunbayo; Bojana Rakic; Jacob Rozmus; Peter Ruben; Bryan Sayson; Saikat Santra; Kirk R Schultz; Kathryn Selby; Paul Shekel; Sandra Sirrs; Cristina Skrypnyk; Andrea Superti-Furga; Stuart E Turvey; Margot I Van Allen; David Wishart; Jiang Wu; John Wu; Dimitrios Zafeiriou; Leo Kluijtmans; Ron A Wevers; Patrice Eydoux; Anna M Lehman; Hilary Vallance; Sylvia Stockler-Ipsiroglu; Graham Sinclair; Wyeth W Wasserman; Clara D van Karnebeek
Journal:  N Engl J Med       Date:  2016-05-25       Impact factor: 91.245

8.  Somatic Hemizygous Y371H CBL Mutation with Loss of Heterozygosity Presenting with BENTA Type Lymphoid Proliferation.

Authors:  Narender Tejwani; Pramod Tayal; Anurag Mehta; Jasmita Dass
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-16       Impact factor: 0.900

9.  Annotating Mutational Effects on Proteins and Protein Interactions: Designing Novel and Revisiting Existing Protocols.

Authors:  Minghui Li; Alexander Goncearenco; Anna R Panchenko
Journal:  Methods Mol Biol       Date:  2017

Review 10.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.